GH Research (NASDAQ:GHRS) PT Raised to $31.00

GH Research (NASDAQ:GHRS) had its price objective raised by Canaccord Genuity Group from $30.00 to $31.00 in a research note published on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

GHRS has been the topic of a number of other reports. HC Wainwright reaffirmed a buy rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, March 4th. JMP Securities decreased their target price on shares of GH Research from $50.00 to $39.00 and set a market outperform rating for the company in a research note on Friday, March 1st.

GH Research Price Performance

Shares of NASDAQ GHRS opened at $11.99 on Monday. GH Research has a 1 year low of $5.05 and a 1 year high of $14.64. The company’s 50-day moving average is $10.51 and its 200 day moving average is $8.07. The stock has a market capitalization of $623.84 million, a P/E ratio of -19.98 and a beta of 0.80.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Research analysts anticipate that GH Research will post -0.96 earnings per share for the current year.

Institutional Trading of GH Research

A number of institutional investors and hedge funds have recently bought and sold shares of GHRS. RTW Investments LP grew its holdings in shares of GH Research by 53.4% during the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after buying an additional 1,158,172 shares during the last quarter. BVF Inc. IL lifted its position in GH Research by 12.1% in the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after acquiring an additional 1,125,000 shares in the last quarter. Lynx1 Capital Management LP boosted its stake in GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after purchasing an additional 133,804 shares during the last quarter. Barclays PLC increased its holdings in shares of GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after purchasing an additional 31,500 shares in the last quarter. Finally, PEAK6 Investments LLC raised its stake in shares of GH Research by 72.9% in the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after purchasing an additional 16,991 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).